Azithropycin according to symptoms — Competitive Intelligence Brief

Azithropycin according to symptoms (Azithropycin according to symptoms) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide antibiotic. Area: Infectious Disease.

marketed Macrolide antibiotic Bacterial 50S ribosomal subunit (23S rRNA) Infectious Disease Small molecule

Target snapshot

Azithropycin according to symptoms (Azithropycin according to symptoms) — University Hospital, Montpellier. Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Azithropycin according to symptoms TARGET	Azithropycin according to symptoms	University Hospital, Montpellier	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
Zithromax	azithromycin	Pfizer Inc.	marketed	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
P.O roxithromycin 150 mg*2/d for 7 days	P.O roxithromycin 150 mg*2/d for 7 days	Western Galilee Hospital-Nahariya	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
azithromycin (AZ)	azithromycin (AZ)	Pfizer	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Intravenous Clarithromycin	Intravenous Clarithromycin	University of Athens	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin 3 days	Azithromycin 3 days	University of Oxford	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
ceftriaxone and azithromycin	ceftriaxone and azithromycin	Sheba Medical Center	marketed	Beta-lactam antibiotic and macrolide antibiotic combination	Bacterial cell wall (ceftriaxone) and bacterial 50S ribosome (azithromycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide antibiotic class)

1. Pfizer · 6 drugs in this class
2. Grünenthal GmbH · 4 drugs in this class
3. Merck Sharp & Dohme LLC · 3 drugs in this class
4. University of Taubate · 2 drugs in this class
5. Lihir Medical Centre · 2 drugs in this class
6. Thomas Jefferson University · 2 drugs in this class
7. Copenhagen Studies on Asthma in Childhood · 1 drug in this class
8. Ain Shams Maternity Hospital · 1 drug in this class
9. Celltrion · 1 drug in this class
10. London School of Hygiene and Tropical Medicine · 1 drug in this class